Cyrus Arash Kholdani, MD
Internal Medicine · Burlington
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 4
Offices
4 locations · Lahey Clinic Inc · Harvard Medical Faculty Phys at Beth Israel Deaconess Med Ctr Inc
Looking this up.
Hospitals listed: Beth Israel Deaconess Hospital-Milton Inc · Beth Israel Deaconess Hospital - Needham · Beth Israel Deaconess Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Kholdani’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A135985 · Cancelled
Licence status: Cancelled · since 2015 · Drexel University College of Medicine.
License has been voluntarily canceled, or the license has been expired for at least five years and has not been renewed. No practice is permitted.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Beth Israel Deaconess Hospital - MiltonMilton, MAAcute Care Hospital · Government - Federal · Has an emergency departmentPart of Beth Israel Lahey Health, which runs 10 hospitalsPatients rate it 3 of 5 · 68% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.41, Oct 2024 – Sep 2025
- Beth Israel Deaconess Hospital - NeedhamNeedham, MAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Beth Israel Lahey Health, which runs 10 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 5 of 5 starsNo measure marked better or worse than the national rate
- Beth Israel Deaconess Medical CenterBoston, MAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Beth Israel Lahey Health, which runs 10 hospitalsHome of Dana-Farber/Harvard Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 79% would definitely recommend itOverall rating: 3 of 5 starsWorse than the national rate — Postoperative hemorrhage or hematoma rate: 3.94 (2.98 to 4.91) · 5,770 cases, Jul 2022 – Jun 2024Worse than the national rate — SSI - Abdominal Hysterectomy: 3.752, Oct 2024 – Sep 2025Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 1,558 cases, Jan 2024 – Dec 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.55, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.565, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.593, Oct 2024 – Sep 2025
See every measure and the patient survey for Beth Israel Deaconess Hospital - Milton
Behind the star rating — Deaths: 3 better, 3 the same, 0 worse of 6 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 1 better, 3 the same, 3 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.41 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.94 (0 to 1.97) · 503 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.83 (0.46 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 7.3 · 119 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 26 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 7.5 · 405 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 11.5 · 459 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 7.8 · 147 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 2,429 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.4) · 5,807 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.26 (0.06 to 0.45) · 5,655 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.35 (1.2 to 5.5) · 1,421 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.55 (0 to 3.22) · 1,069 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.29 (0.69 to 3.9) · 1,330 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.77 (1.09 to 16.44) · 1,083 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.72 (0.93 to 8.51) · 1,070 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.04 (0.53 to 3.54) · 140 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.24 (0 to 1.08) · 4,053 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 2.9 · 761 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.579 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.876 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.9 · 505 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 20.5 · 457 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 13.5 · 472 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.4 · 509 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.9 · 763 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 156 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.1 (10.2 to 16.5) · 2,232 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.4) · 401 cases | No different | Jan 2024 – Dec 2024 |
What patients said (405 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 67% |
| Nurses "always" communicated well | 78% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 75% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 66% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 74% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 68% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
See every measure and the patient survey for Beth Israel Deaconess Hospital - Needham
Behind the star rating — Deaths: 3 better, 2 the same, 0 worse of 5 measures. Safety: 0 better, 6 the same, 0 worse of 6 measures. Readmissions: 0 better, 5 the same, 2 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.97 (0 to 2.01) · 408 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.88 (0.46 to 1.3) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 7.8 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8 · 491 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 9.5 · 716 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10 · 150 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 1,829 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.4) · 4,910 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.31 (0.11 to 0.51) · 4,857 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.36 (0.94 to 5.77) · 390 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.48 (0.81 to 4.15) · 369 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.71 (0.2 to 3.22) · 111 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.25 (0 to 1.1) · 3,674 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.182 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.524 | No different | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.641 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.601 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 23.2 · 517 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 22 · 547 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 4.4 · 768 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.2 · 740 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.1 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (10.3 to 16.4) · 2,584 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.3) · 619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (712 patients answered, 28% of those asked)
| Cleanliness | 3 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 2 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 63% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 68% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 45% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Beth Israel Deaconess Medical Center
Behind the star rating — Deaths: 4 better, 4 the same, 0 worse of 8 measures. Safety: 3 better, 4 the same, 1 worse of 8 measures. Readmissions: 0 better, 7 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Postoperative hemorrhage or hematoma rateComplications and deaths | 3.94 (2.98 to 4.91) · 5,770 cases | Worse | Jul 2022 – Jun 2024 |
| SSI - Abdominal HysterectomyInfections | 3.752 | Worse | Oct 2024 – Sep 2025 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.3 to 14.4) · 1,558 cases | Worse | Jan 2024 – Dec 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.55 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.565 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.593 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.07 (0.4 to 1.74) · 4,681 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.03 (0.85 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 182.52 (157.03 to 208.01) · 432 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.3 · 342 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.7 · 170 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.3 · 366 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.9 · 964 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 11 · 620 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.3 · 554 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 6,560 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0.04 to 0.33) · 17,760 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.11 to 0.43) · 18,937 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.73 (2.48 to 4.99) · 6,442 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.53 (0.47 to 2.6) · 3,059 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.37 (3.07 to 9.67) · 2,892 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.05 (3.85 to 8.26) · 3,016 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.33 (0.11 to 2.54) · 1,427 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.84 (0.49 to 1.19) · 16,829 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 252 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.884 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.145 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.3 · 629 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.9 · 1,411 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 25.9 · 583 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 30.3 · 1,235 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7.3 · 673 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.1 · 767 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5 (4.2 to 6.1) · 1,558 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.7 · 245 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.2 · 233 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.1 · 239 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (10.2 to 14.9) · 5,120 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.3) · 1,196 cases | No different | Jan 2024 – Dec 2024 |
What patients said (5,505 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 72% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 64% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 75% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 78% |
| Nurses "always" explained things so they could understand | 78% |
| Nurses "always" listened carefully | 80% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 51% |
| "YES", patients would definitely recommend the hospital | 79% |
| Staff "always" explained possible side effects | 51% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$60,981
Medicare paid this office $60,981 for 531 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Critical care, first 30-74 minutes | 68 | $23,744 | $172 |
| Long return visit (40+ min) | 57 | $8,169 | $117 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 36 | $5,796 | $93 |
| Return visit (30+ min) | 31 | $3,698 | $106 |
| Long return visit (40+ min) | 20 | $3,626 | $151 |
See all 22 services
| Critical care, first 30-74 minutes | 68 | $23,744 | $172 |
| Long return visit (40+ min) | 57 | $8,169 | $117 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 36 | $5,796 | $93 |
| Return visit (30+ min) | 31 | $3,698 | $106 |
| Long return visit (40+ min) | 20 | $3,626 | $151 |
| Return visit (30+ min) | 37 | $2,882 | $70 |
| New patient visit (60+ min) | 13 | $1,779 | $137 |
| Test to measure expiratory airflow and volume | 246 | $1,655 | $6 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 13 | $1,235 | $41 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 15 | $1,170 | $69 |
| Test to examine how well the lungs exchange gases | 132 | $971 | $7 |
| Insertion of tube in right heart chambers for measurement | 11 | $947 | $86 |
| Test to determine lung volumes using sensors | 33 | $332 | $10 |
| Test for exercise-induced lung stress | 16 | $309 | $18 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 11 | $288 | $26 |
| Test to determine lung volumes using gas dilution or washout | 28 | $263 | $9 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 18 | $249 | $14 |
| Test to measure expiratory airflow and volume | 33 | $222 | $7 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 11 | $207 | $14 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 26 | $202 | $8 |
| Ultrasonic guidance for blood vessel access | 11 | $135 | $11 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 11 | $101 | $9 |
Who their Medicare patients are
531 Original Medicare patients in 2024. Average age 75 · Under 65 9% · 85 and older 13% · Women 58% · Also on Medicaid 23% · Health risk score 2.25. Above the middle of the specialty; the typical internal medicine clinician is at 1.76.
Conditions among them: High blood pressure 75% · COPD 48% · Heart failure 42% · Coronary heart disease 39% · Chronic kidney disease 37% · Diabetes 36% · Atrial fibrillation 33% · Depression 30% · Cancer 27% · Dementia 11% · Stroke 9%.
The office billed $260,053, Medicare allowed $79,195 and paid $60,981; for 1,089 services of 30 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 531 | 1,089 | 75 | 2.25 | $260,053 | $60,981 |
| 2023 | 431 | 888 | 73 | 2.41 | $271,910 | $64,263 |
| 2022 | 376 | 785 | 72 | 2.45 | $259,745 | $61,973 |
| 2021 | 485 | 1,054 | 72 | 2.38 | $347,064 | $86,416 |
| 2020 | 517 | 1,137 | 72 | 2.58 | $310,767 | $80,613 |
| 2019 | 510 | 1,075 | 71 | 2.51 | $263,702 | $68,685 |
| 2018 | 398 | 761 | 70 | 2.54 | $142,399 | $39,803 |
| 2017 | 156 | 425 | 67 | 2.65 | $136,482 | $34,522 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 15 services
| Critical care, first 30-74 minutes | 82 | $29,293 | $178 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 58 | $11,687 | $101 |
| Return visit (30+ min) | 59 | $6,711 | $79 |
| Long return visit (40+ min) | 43 | $5,802 | $109 |
| Insertion of tube in right heart chambers for measurement | 17 | $1,870 | $104 |
| New patient visit (60+ min) | 11 | $1,652 | $150 |
| Test to measure expiratory airflow and volume | 193 | $1,331 | $7 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 11 | $769 | $70 |
| Test to examine how well the lungs exchange gases | 91 | $675 | $7 |
| Test for exercise-induced lung stress | 16 | $297 | $19 |
| Test to determine lung volumes using gas dilution or washout | 24 | $230 | $10 |
| Test to determine lung volumes using sensors | 19 | $190 | $10 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 14 | $156 | $10 |
| Ultrasonic guidance for blood vessel access | 12 | $153 | $12 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 15 | $120 | $8 |
2022: 13 services
| Critical care, first 30-74 minutes | 57 | $25,594 | $184 |
| Long return visit (40+ min) | 73 | $15,773 | $119 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 41 | $6,241 | $88 |
| Return visit (30+ min) | 37 | $3,272 | $78 |
| Insertion of tube in right heart chambers for measurement | 20 | $2,162 | $108 |
| New patient visit (60+ min) | 12 | $1,740 | $145 |
| Critical care, each additional 30 minutes | 15 | $1,686 | $94 |
| Test to measure expiratory airflow and volume | 163 | $1,173 | $7 |
| Test to examine how well the lungs exchange gases | 68 | $519 | $8 |
| Test to determine lung volumes using sensors | 25 | $253 | $10 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 14 | $150 | $11 |
| Test to determine lung volumes using gas dilution or washout | 11 | $103 | $9 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 12 | $101 | $8 |
2021: 15 services
| Critical care, first 30-74 minutes | 105 | $39,998 | $190 |
| Long return visit (40+ min) | 54 | $8,991 | $125 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 52 | $8,875 | $91 |
| Telephone medical discussion with physician, 21-30 minutes | 55 | $7,340 | $84 |
| Return visit (30+ min) | 59 | $6,289 | $84 |
| New patient visit (60+ min) | 23 | $3,614 | $157 |
| Insertion of tube in right heart chambers for measurement | 28 | $3,362 | $112 |
| Critical care, each additional 30 minutes | 15 | $1,636 | $96 |
| Test to measure expiratory airflow and volume | 191 | $1,425 | $7 |
| Test to examine how well the lungs exchange gases | 92 | $760 | $8 |
| Test to determine lung volumes using gas dilution or washout | 30 | $320 | $11 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 28 | $256 | $9 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 20 | $230 | $11 |
| Test to determine lung volumes using sensors | 17 | $182 | $11 |
| Ultrasonic guidance for blood vessel access | 11 | $133 | $12 |
2020: 17 services
| Critical care, first 30-74 minutes | 82 | $40,828 | $193 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 52 | $9,213 | $91 |
| Return visit (30+ min) | 61 | $5,203 | $66 |
| Telephone medical discussion with physician, 21-30 minutes | 54 | $4,974 | $67 |
| New patient visit (60+ min) | 26 | $3,851 | $148 |
| Long return visit (40+ min) | 28 | $3,389 | $94 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 17 | $2,978 | $175 |
| Insertion of tube in right heart chambers for measurement | 18 | $2,210 | $111 |
| Test to measure expiratory airflow and volume | 243 | $1,811 | $7 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 14 | $1,048 | $75 |
| Test to examine how well the lungs exchange gases | 118 | $937 | $8 |
| Test for exercise-induced lung stress | 25 | $502 | $20 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 40 | $458 | $11 |
| Test to determine lung volumes using gas dilution or washout | 41 | $443 | $11 |
| Test to determine lung volumes using sensors | 21 | $226 | $11 |
| Ultrasonic guidance for blood vessel access | 15 | $226 | $13 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 18 | $204 | $10 |
2019: 15 services
| Critical care, first 30-74 minutes | 66 | $28,150 | $190 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 42 | $6,821 | $89 |
| Return visit (30+ min) | 63 | $6,364 | $68 |
| Long return visit (40+ min) | 46 | $5,692 | $88 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 29 | $4,958 | $171 |
| New patient visit (60+ min) | 31 | $4,504 | $145 |
| Insertion of tube in right heart chambers for measurement | 26 | $3,370 | $116 |
| Test to measure expiratory airflow and volume | 261 | $1,977 | $7 |
| Test to examine how well the lungs exchange gases | 119 | $966 | $8 |
| Short return visit (20+ min) | 18 | $799 | $42 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 41 | $454 | $11 |
| Test for exercise-induced lung stress | 22 | $438 | $20 |
| Test to determine lung volumes using gas dilution or washout | 35 | $375 | $11 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 23 | $268 | $11 |
| Test to determine lung volumes using sensors | 24 | $246 | $10 |
2018: 19 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 39 | $8,831 | $91 |
| Critical care, first 30-74 minutes | 17 | $5,891 | $190 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 26 | $4,706 | $174 |
| Long return visit (40+ min) | 28 | $3,085 | $93 |
| New patient visit (60+ min) | 18 | $2,480 | $138 |
| Return visit (30+ min) | 33 | $2,387 | $68 |
| New patient visit (60+ min) | 11 | $1,606 | $146 |
| Insertion of tube in right heart chambers for measurement | 11 | $1,241 | $113 |
| Test to measure expiratory airflow and volume | 128 | $943 | $7 |
| Test for exercise-induced lung stress | 41 | $851 | $20 |
| Test to examine how well the lungs exchange gases | 81 | $649 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 32 | $372 | $12 |
| Test to determine lung volumes using sensors | 32 | $348 | $11 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 26 | $303 | $12 |
| Test to determine lung volumes using sensors | 21 | $231 | $11 |
| Test to examine how well the lungs exchange gases | 23 | $187 | $8 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 16 | $176 | $11 |
| Test to determine lung volumes using gas dilution or washout | 13 | $138 | $11 |
| Test to measure expiratory airflow and volume | 17 | $129 | $8 |
2017: 11 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 22 | $10,937 | $93 |
| Long return visit (40+ min) | 21 | $2,490 | $89 |
| New patient visit (60+ min) | 14 | $2,056 | $147 |
| Return visit (30+ min) | 19 | $1,789 | $66 |
| New patient visit (60+ min) | 12 | $1,730 | $144 |
| Hospital discharge day management, more than 30 minutes | 13 | $1,669 | $98 |
| Pulmonary exercise testing | 31 | $853 | $28 |
| Return visit (30+ min) | 11 | $826 | $69 |
| Test to examine how well the lungs exchange gases | 22 | $180 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 11 | $130 | $12 |
| Test to measure expiratory airflow and volume | 12 | $91 | $8 |
Medicaid work
$466 in 2024
Medicaid paid $466 for 138 billed services this clinician did in 2024, up to 25 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation | 125 | $427 |
| Diffusing capacity | 13 | $39 |
| 2024 | 138 | 2 | 25 | $466 |
| 2023 | 164 | 3 | 51 | $1,550 |
| 2022 | 31 | 1 | 15 | $79 |
| 2021 | 129 | 3 | 19 | $5,269 |
| 2020 | 112 | 2 | 15 | $7,924 |
| 2019 | 138 | 3 | 35 | $1,307 |
| 2018 | 77 | 4 | 20 | $636 |
See the largest Medicaid services in earlier years
2023
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 36 | $1,062 |
| Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation | 98 | $354 |
| Diffusing capacity | 30 | $134 |
2022
| Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation | 31 | $79 |
2021
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 66 | $5,160 |
| Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation | 50 | $78 |
| Diffusing capacity | 13 | $31 |
2020
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 69 | $7,806 |
| Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation | 43 | $118 |
2019
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 25 | $1,115 |
| Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation | 80 | $117 |
| Diffusing capacity | 33 | $74 |
2018
| EVALUATION OF WHEEZING | 14 | $275 |
| PULMONARY STRESS TESTING | 12 | $141 |
| Diffusing capacity | 20 | $137 |
| Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation | 31 | $83 |
Drugs they prescribed that Part D paid
$3,090,641
Pharmacies billed $3,090,641 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 540) in 2024. At or below the middle of the specialty; the typical internal medicine clinician is at 1%.
314 generic and 226 brand-name prescriptions · $3,090,641 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Uptravi | 43 | $1,008,771 | $23,460 |
| Opsumit | 64 | $779,860 | $12,185 |
| Tyvaso Dpi | 26 | $643,920 | $24,766 |
| Winrevair | 17 | $290,722 | $17,101 |
| Ambrisentan | 57 | $150,117 | $2,634 |
See all 12 drugs
| Uptravi | 43 | $1,008,771 | $23,460 |
| Opsumit | 64 | $779,860 | $12,185 |
| Tyvaso Dpi | 26 | $643,920 | $24,766 |
| Winrevair | 17 | $290,722 | $17,101 |
| Ambrisentan | 57 | $150,117 | $2,634 |
| Sildenafil Citrate | 92 | $45,355 | $493 |
| Tadalafil | 65 | $7,701 | $118 |
| Anoro Ellipta | 13 | $6,987 | $537 |
| Albuterol Sulfate Hfa | 24 | $1,106 | $46 |
| Torsemide | 12 | $225 | $19 |
| Fluticasone Propionate | 11 | $176 | $16 |
| Furosemide | 24 | $109 | $5 |
Year by year
| 2024 | 540 | 58 | 0% (0) | 42% | $3,090,641 |
| 2023 | 533 | 60 | 0% (0) | 42% | $2,752,475 |
| 2022 | 578 | 64 | 0% (0) | 40% | $2,484,355 |
| 2021 | 677 | 78 | None | 48% | $3,044,660 |
| 2020 | 672 | 59 | 0% (0) | 53% | $3,979,130 |
| 2019 | 487 | 64 | 0% (0) | 58% | $2,528,641 |
| 2018 | 207 | 46 | 0% (0) | 52% | $657,861 |
| 2017 | 159 | 29 | None | 57% | $561,049 |
| 2015 | 31 | None | 0% (0) | 61% | $3,415 |
| 2014 | 42 | None | 0% (0) | 62% | $4,426 |
| 2013 | 32 | 11 | None | 41% | $1,839 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 12 drugs
| Uptravi | 49 | $1,144,479 | $23,357 |
| Opsumit | 76 | $948,143 | $12,476 |
| Ambrisentan | 53 | $189,224 | $3,570 |
| Tadalafil | 69 | $100,222 | $1,452 |
| Sildenafil Citrate | 102 | $45,718 | $448 |
| Alyq | 14 | $24,188 | $1,728 |
| Spiriva Respimat | 16 | $11,046 | $690 |
| Anoro Ellipta | 14 | $8,188 | $585 |
| Incruse Ellipta | 14 | $6,093 | $435 |
| Albuterol Sulfate Hfa | 22 | $1,157 | $53 |
| Leflunomide | 12 | $286 | $24 |
| Furosemide | 17 | $104 | $6 |
2022: 12 drugs
| Uptravi | 42 | $891,087 | $21,216 |
| Opsumit | 71 | $828,761 | $11,673 |
| Ambrisentan | 62 | $359,642 | $5,801 |
| Tadalafil | 62 | $114,436 | $1,846 |
| Sildenafil Citrate | 118 | $46,086 | $391 |
| Alyq | 12 | $23,149 | $1,929 |
| Spiriva Respimat | 23 | $17,294 | $752 |
| Spiriva Handihaler | 15 | $7,371 | $491 |
| Incruse Ellipta | 13 | $4,879 | $375 |
| Albuterol Sulfate Hfa | 25 | $1,208 | $48 |
| Torsemide | 14 | $326 | $23 |
| Furosemide | 32 | $152 | $5 |
2021: 14 drugs
| Opsumit | 96 | $1,038,402 | $10,817 |
| Uptravi | 53 | $941,595 | $17,766 |
| Ambrisentan | 56 | $368,416 | $6,579 |
| Orenitram Er | 25 | $256,216 | $10,249 |
| Adempas | 11 | $126,722 | $11,520 |
| Sildenafil Citrate | 171 | $72,299 | $423 |
| Tadalafil | 38 | $59,301 | $1,561 |
| Alyq | 13 | $25,805 | $1,985 |
| Trelegy Ellipta | 11 | $6,496 | $591 |
| Spiriva | 13 | $6,316 | $486 |
| Incruse Ellipta | 15 | $5,528 | $369 |
| Albuterol Sulfate Hfa | 16 | $803 | $50 |
| Torsemide | 22 | $762 | $35 |
| Furosemide | 50 | $421 | $8 |
2020: 12 drugs
| Uptravi | 93 | $1,668,361 | $17,939 |
| Opsumit | 93 | $942,466 | $10,134 |
| Orenitram Er | 39 | $436,321 | $11,188 |
| Ambrisentan | 64 | $422,518 | $6,602 |
| Letairis | 17 | $177,357 | $10,433 |
| Adempas | 12 | $130,782 | $10,899 |
| Sildenafil Citrate | 163 | $69,233 | $425 |
| Alyq | 25 | $53,408 | $2,136 |
| Breo Ellipta | 11 | $4,152 | $377 |
| Torsemide | 26 | $965 | $37 |
| Albuterol Sulfate Hfa | 16 | $898 | $56 |
| Furosemide | 33 | $145 | $4 |
2019: 11 drugs
| Uptravi | 67 | $1,132,998 | $16,910 |
| Opsumit | 54 | $526,645 | $9,753 |
| Letairis | 22 | $210,845 | $9,584 |
| Orenitram Er | 45 | $174,374 | $3,875 |
| Ambrisentan | 14 | $96,811 | $6,915 |
| Revatio | 11 | $90,874 | $8,261 |
| Sildenafil Citrate | 125 | $39,285 | $314 |
| Alyq | 12 | $26,937 | $2,245 |
| Torsemide | 21 | $771 | $37 |
| Albuterol Sulfate Hfa | 13 | $636 | $49 |
| Furosemide | 22 | $104 | $5 |
2018: 5 drugs
| Letairis | 40 | $383,668 | $9,592 |
| Opsumit | 18 | $161,989 | $8,999 |
| Sildenafil | 43 | $18,726 | $435 |
| Spironolactone | 19 | $247 | $13 |
| Furosemide | 17 | $65 | $4 |
2017: 4 drugs
| Letairis | 52 | $479,458 | $9,220 |
| Adcirca | 11 | $42,283 | $3,844 |
| Sildenafil | 19 | $6,202 | $326 |
| Spironolactone | 17 | $147 | $9 |
2014: 1 drug
| Proair Hfa | 13 | $1,076 | $83 |
Money from drug and device companies
$552 in 2025
| 2025 | 1 | 5 | None | $552 |
| 2024 | 5 | 10 | $2,700 | $3,448 |
| 2023 | 3 | 6 | $3,483 | $3,830 |
| 2022 | 2 | 21 | $975 | $1,901 |
| 2021 | 4 | 27 | $3,900 | $4,561 |
| 2020 | 1 | 1 | $2,000 | $2,000 |
| 2019 | 2 | 2 | None | $146 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| United Therapeutics | Tyvaso | $552 | 5 payments
|
See all 5 published payments
| United Therapeutics | Meals · 2025-11-17 | None | $147 |
| United Therapeutics | Meals · 2025-10-08 | Tyvaso | $90 |
| United Therapeutics | Meals · 2025-09-28 | None | $59 |
| United Therapeutics | Meals · 2025-04-29 | Tyvaso | $119 |
| United Therapeutics | Meals · 2025-02-19 | Remodulin | $139 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $3,448
| Beckman Coulter | Dxi 9000 Access Immunoassay Analyzer | $2,500 | 1 payment
|
| United Therapeutics | Tyvaso | $613 | 6 payments
|
| Bayer Healthcare Pharmaceuticals | Adempas | $200 | 1 payment
|
| Actelion Pharmaceuticals US | None | $77 | 1 payment
|
| Genzyme | None | $59 | 1 payment
|
2023: $3,830
| Actelion Pharmaceuticals US | Opsumit | $3,529 | 4 payments
|
| Bayer Healthcare Pharmaceuticals | Adempas | $200 | 1 payment
|
| United Therapeutics | Remodulin | $102 | 1 payment
|
2022: $1,901
| Actelion Pharmaceuticals US | Opsumit | $1,646 | 15 payments
|
| United Therapeutics | Tyvaso | $255 | 6 payments
|
2021: $4,561
| Acceleron Pharma | None | $3,900 | 1 payment
|
| United Therapeutics | Tyvaso | $297 | 7 payments
|
| Actelion Pharmaceuticals US | Uptravi | $242 | 18 payments
|
| Bayer HealthCare Pharmaceuticals | Adempas | $122 | 1 payment
|
2020: $2,000
| United Therapeutics | Orenitram | $2,000 | 1 payment
|
2019: $146
| Actelion Pharmaceuticals US | None | $125 | 1 payment
|
| Janssen Research & Development | Opsumit | $21 | 1 payment
|
Professional record
- NPI
- 1235373796
- Licence
- CA A135985, MA 274661California A135985: Cancelled
- Group
- Lahey Clinic Inc · Harvard Medical Faculty Phys at Beth Israel Deaconess Med Ctr Inc
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RP1001X (207RP1001X); Federal specialty code 207RC0200X (207RC0200X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2009-04-28
- NPI last updated
- 2022-09-08
- NPI record certified
- 2022-09-08
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 300 Pasteur Dr, Stanford, CA, 94305